Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader
•
Tue, Jun 12, 2012
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
98 people get VRUS articles and Market Currents by email alert.
Get email alerts on VRUS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
John Paulson's Big 2012 BetsAlpha Stratus • Wed, May 30, 2012 -
Joe DiMenna's Top Stock PicksInsider Monkey • Sat, Mar 17, 2012 -
-
Hepatitis C Remains A Hot PlayThe Burrill Report • Mon, Feb 27, 2012 -
-
-
11 Large-Cap, Low Debt Stocks For Defensive InvestorsInsider Monkey • Mon, Jan 30, 2012
-
-
Top Healthcare Stocks With The Highest Upside PotentialInsider Monkey • Wed, Jan 25, 2012
-
-
-
2 Major Biotech Trends In 2012Marc Lichtenfeld • Thu, Jan 19, 2012 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Idenix Pharmaceuticals: A Hepatitis C Play RevisitedEXPstocktrader • Tue, Jun 12, 2012
-
John Paulson's Big 2012 BetsAlpha Stratus • Wed, May 30, 2012
-
Joe DiMenna's Top Stock PicksInsider Monkey • Sat, Mar 17, 2012
-
-
Hepatitis C Remains A Hot PlayThe Burrill Report • Mon, Feb 27, 2012
-
-
-
11 Large-Cap, Low Debt Stocks For Defensive InvestorsInsider Monkey • Mon, Jan 30, 2012
-
-
Top Healthcare Stocks With The Highest Upside PotentialInsider Monkey • Wed, Jan 25, 2012
-
-
-
2 Major Biotech Trends In 2012Marc Lichtenfeld • Thu, Jan 19, 2012
-
-
-
-
-
-
-
-
PR Newswire (Dec 16, 2011)
-
at CNBC.com (Nov 22, 2011)
-
at MarketWatch.com (Nov 21, 2011)
-
at MarketWatch.com (Nov 21, 2011)
-
at MarketWatch.com (Nov 21, 2011)
-
at MarketWatch.com (Nov 21, 2011)
-
at MarketWatch.com (Oct 10, 2011)
-
at MarketWatch.com (Sep 6, 2011)
-
at MarketWatch.com (Jul 6, 2011)
-
at CNBC.com (Jun 9, 2011)
-
at MarketWatch.com (Jun 8, 2011)
-
at MarketWatch.com (Jun 8, 2011)
-
at MarketWatch.com (May 24, 2011)
-
at MarketWatch.com (Apr 25, 2011)
-
at MarketWatch.com (Apr 25, 2011)
-
at MarketWatch.com (Apr 25, 2011)
-
at CNBC.com (Apr 8, 2011)
-
at CNBC.com (Apr 5, 2011)
-
at MarketWatch.com (Mar 31, 2011)
-
at MarketWatch.com (Mar 31, 2011)
VRUS vs. ETF Alternatives
Company Description
Currently, there's no company description for VRUS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 7, 2011, 5:27 PM While Pharmasset (VRUS) shareholders stand to reap a windfall from Gilead Sciences’ (GILD) $11B takeover offer, its top execs are also in line for fat paydays. According to SEC filings reviewed by Footnoted, VRUS CEO P. Schaefer Price could pocket $255M once the deal closes, and other top brass also would grow much richer. Comment! [M&A, Healthcare]
- Thursday, December 1, 2011, 2:36 PM Benzinga notes shares of Pharmasset (VRUS -1.4%) are trading a little funky this week considering the strong market rally and its blockbuster sale to Gilead Sciences (GILD -0.4%). Despite a pickup in chatter that the deal is in jeopardy - a check with analysts covering GILD say the merger is still a "go." Comment! [M&A, Healthcare]
- Monday, November 21, 2011, 7:17 AM Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmasset on Friday. 2 Comments [M&A, Healthcare]
- Thursday, September 8, 2011, 1:35 PM Pharmasset (VRUS +4%) shares are on the move after favorable analyst notes: Piper Jaffray initiates coverage at Overweight, and Brean Murray raises its price target to $105 from $87. On top of that, Briefing.com reports hearing that a firm has issued positive comments regarding the company's potential valuation in an M&A scenario. Comment! [Healthcare, On the Move, M&A]
-
Michael Kudrna
EXPstocktrader: The Hepatitis C Gold Rush $IDIX $ILMN $INHX $MRK $VRUS $$ #biotech #KSMT http://bit.ly/zInIwE - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Impressive. "Gilead to pay $11B to buy Pharmasset." Buy Gilead Sciences (GILD) on Pharmasset (VRUS) integration. http://bit.ly/vcSVoq - View all 0 replies
-
Asif Suria
Gilead to buy Pharmasset for $11 billion for $11 billion $GILD $VRUS http://reut.rs/voSBc3 - View all 0 replies
-
- View all 9 replies
-
-
-
- View all 0 replies
-
- View all 5 replies
-
talbano: it got sold ah on Friday 20k shares, i almost dumped it seeing that ...glad i didn't
-
LATEST REPLIES
-
- View all 9 replies
-
-
-
- View all 5 replies
-
talbano: it got sold ah on Friday 20k shares, i almost dumped it seeing that ...glad i didn't
-
-
Michael Bryant
I don't think I want to bet big on Inhibitex (INHX), but Pharmasset (VRUS) is a winner. http://bit.ly/vl8iO5 - View all 2 replies
-
-
-
Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 1 replies
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.